Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis	Skin and Connective Tissue Diseases, arteritis, autoimmune disease, autoimmune disorder of the nervous system, brain disorder, cardiovascular disorder, central nervous system disorder, central nervous system vasculitis, cerebrovascular disorder, immune system disorder, nervous system disorder, skin disorder, skin vascular disease, temporal arteritis, vascular disorder, vasculitis	Recruiting	Phase 2	2026-08-10		NCT07108387

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Institute of Allergy and Infectious Diseases (NIAID)	402

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Emory University School of Medicine: Division of Rheumatology	Atlanta	United States	2
Hospital for Special Surgery, New York: Division of Rheumatology	New York	United States	2
Johns Hopkins Hospital: Division of Rheumatology Vasculitis Center	Baltimore	United States	1
Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases	Boston	United States	1
Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology	Great Neck	United States	2
Northwestern University	Chicago	United States	727
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology	Pittsburgh	United States	1